Literature DB >> 27374003

Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.

David Goldberg1, Benjamin French2, Craig Newcomb3, Qing Liu3, Gurvaneet Sahota4, Anna E Wallace4, Kimberly A Forde5, James D Lewis6, Scott D Halpern7.   

Abstract

BACKGROUND & AIMS: Despite recent attention to differences in access to livers for transplantation, research has focused on patients already on the wait list. We analyzed data from a large administrative database that represents the entire US population, and state Medicaid data, to identify factors associated with differences in access to wait lists for liver transplantation.
METHODS: We performed a retrospective cohort study of transplant-eligible patients with end-stage liver disease using the HealthCore Integrated Research Database (2006-2014; n = 16,824) and Medicaid data from 5 states (2002-2009; California, Florida, New York, Ohio, and Pennsylvania; n = 67,706). Transplant-eligible patients had decompensated cirrhosis, hepatocellular carcinoma (HCC), and/or liver synthetic dysfunction, based on validated International Classification of Diseases, Ninth Revision-based algorithms and data from laboratory studies. Placement on the wait list was determined through linkage with the Organ Procurement and Transplantation Network database.
RESULTS: In an unadjusted analysis of the HealthCore database, we found that 29% of patients with HCC were placed on the 2-year wait list (95% confidence interval [CI], 25.4%-33.0%) compared with 11.9% of patients with stage 4 cirrhosis (ascites) (95% CI, 11.0%-12.9%) and 12.6% of patients with stage 5 cirrhosis (ascites and variceal bleeding) (95% CI, 9.4%-15.2%). Among patients with each stage of cirrhosis, those with HCC were significantly more likely to be placed on the wait list; adjusted subhazard ratios ranged from 1.7 (for patients with stage 5 cirrhosis and HCC vs those without HCC) to 5.8 (for patients with stage 1 cirrhosis with HCC vs those without HCC). Medicaid beneficiaries with HCC were also more likely to be placed on the transplant wait list, compared with patients with decompensated cirrhosis, with a subhazard ratio of 2.34 (95% CI, 2.20-2.49). Local organ supply and wait list level demand were not associated with placement on the wait list.
CONCLUSIONS: In an analysis of US healthcare databases, we found patients with HCC to be more likely to be placed on liver transplant wait lists than patients with decompensated cirrhosis. Previously reported reductions in access to transplant care for wait-listed patients with decompensated cirrhosis underestimate the magnitude of this difference.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disparities; Liver Cancer; UNOS; Wait List

Mesh:

Year:  2016        PMID: 27374003      PMCID: PMC5069141          DOI: 10.1016/j.cgh.2016.06.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

1.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

2.  Cardiovascular events and death in children exposed and unexposed to ADHD agents.

Authors:  Hedi Schelleman; Warren B Bilker; Brian L Strom; Stephen E Kimmel; Craig Newcomb; James P Guevara; Gregory W Daniel; Mark J Cziraky; Sean Hennessy
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

3.  Addressing geographic disparities in liver transplantation through redistricting.

Authors:  S E Gentry; A B Massie; S W Cheek; K L Lentine; E H Chow; C E Wickliffe; N Dzebashvili; P R Salvalaggio; M A Schnitzler; D A Axelrod; D L Segev
Journal:  Am J Transplant       Date:  2013-07-09       Impact factor: 8.086

4.  Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.

Authors:  Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-27       Impact factor: 2.890

5.  Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database.

Authors:  D Goldberg; Jd Lewis; Sd Halpern; Mark Weiner; Vincent Lo Re
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-06-04       Impact factor: 2.890

6.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

7.  Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.

Authors:  Patrick Grant Northup; Nicolas Michael Intagliata; Neeral Lalit Shah; Shawn Joseph Pelletier; Carl Lansing Berg; Curtis Kent Argo
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

8.  Use of Population-based Data to Demonstrate How Waitlist-based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care.

Authors:  D S Goldberg; B French; G Sahota; A E Wallace; J D Lewis; S D Halpern
Journal:  Am J Transplant       Date:  2016-05-17       Impact factor: 8.086

9.  Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database.

Authors:  David S Goldberg; James D Lewis; Scott D Halpern; Mark G Weiner; Vincent Lo Re
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-11-04       Impact factor: 2.890

10.  Survival benefit-based deceased-donor liver allocation.

Authors:  D E Schaubel; M K Guidinger; S W Biggins; J D Kalbfleisch; E A Pomfret; P Sharma; R M Merion
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

View more
  12 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Increased Distance to a Liver Transplant Center Is Associated With Higher Mortality for Patients With Chronic Liver Failure.

Authors:  David S Goldberg; Craig Newcomb; Richard Gilroy; Gurvaneet Sahota; Anna E Wallace; James D Lewis; Scott D Halpern
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-27       Impact factor: 11.382

3.  Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.

Authors:  Ju Dong Yang; Joseph J Larson; Kymberly D Watt; Alina M Allen; Russell H Wiesner; Gregory J Gores; Lewis R Roberts; Julie A Heimbach; Michael D Leise
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

4.  Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.

Authors:  K Atiemo; A Skaro; H Maddur; L Zhao; S Montag; L VanWagner; S Goel; A Kho; B Ho; R Kang; J L Holl; M M Abecassis; J Levitsky; D P Ladner
Journal:  Am J Transplant       Date:  2017-04-04       Impact factor: 8.086

5.  Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?

Authors:  Tamás Benkö; Julia König; Jens M Theysohn; Clemens Schotten; Fuat H Saner; Jürgen Treckmann; Sonia Radunz
Journal:  Eur J Med Res       Date:  2022-05-26       Impact factor: 4.981

6.  Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.

Authors:  Ju Dong Yang; Ajitha Mannalithara; Andrew J Piscitello; John B Kisiel; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

7.  Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Mounika Kanneganti; Nadim Mahmud; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Transplantation       Date:  2020-01       Impact factor: 5.385

8.  Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.

Authors:  Anton L V Avanceña; Nicholas Miller; Sarah E Uttal; David W Hutton; Jessica L Mellinger
Journal:  J Hepatol       Date:  2020-12-14       Impact factor: 30.083

9.  Accurate long-term prediction of death for patients with cirrhosis.

Authors:  David Goldberg; Alejandro Mantero; David Kaplan; Cindy Delgado; Binu John; Nadine Nuchovich; Ezekiel Emanuel; Peter P Reese
Journal:  Hepatology       Date:  2022-04-01       Impact factor: 17.298

10.  Recent trends in liver transplantation for alcoholic liver disease in the United States.

Authors:  Catherine E Kling; James D Perkins; Robert L Carithers; Dennis M Donovan; Lena Sibulesky
Journal:  World J Hepatol       Date:  2017-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.